



## **PRESS RELEASE**

### **Crucell to Release 2005 Earnings on Tuesday, January 24, 2006**

**Leiden, The Netherlands, January 13, 2006** – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) today announced that it will release its full-year 2005 financial results on Tuesday, January 24, 2006 at 13:30 p.m. Central European Time (CET) (7:30 a.m. US Eastern Daylight Time).

An hour later, at 14:30 p.m. CET, Crucell will conduct a conference call open to all, which will also be webcast. To participate in the conference call, please call one of the following toll-free numbers 10 minutes prior to commencement:

**866-328-4274 for the US;  
0800-358-5255 for the UK; and  
0800-265-8531 for the Netherlands.**

Following a presentation of the results you will be able to ask questions during a question and answer session.

The live audio webcast can be accessed via the homepage of Crucell's website at [www.crucell.com](http://www.crucell.com), and will be archived and available for replay following the event.

#### **About Crucell**

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The Company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6<sup>®</sup> production technology. The company also licenses its PER.C6<sup>®</sup> technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit [www.crucell.com](http://www.crucell.com).

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).*



**For further information please contact:**

**Crucell N.V.**

Harry Suykerbuyk  
Director Investor Relations and  
Corporate Communications  
Tel. +31 (0)71 524 8718  
[h.suykerbuyk@crucell.com](mailto:h.suykerbuyk@crucell.com)

**For Crucell N.V. in the USA:**

**Redington Inc.**  
Thomas Redington  
Tel. +1 212-926-1733  
[tredington@redingtoninc.com](mailto:tredington@redingtoninc.com)